Recent evidence points to the usefulness of new technologies like rtCGM and insulin pumps to improve metabolic control, as this may preserve C-peptide and other outcomes, both with and without additional immunomodulatory therapy at the onset of T1DM (25). The gene discussed is INS; the disease is type 1 diabetes mellitus.